Physician profile
Adel Metry
NPI 1376638809
$1,423.27
in general payments reported to CMS, 2019-2025
12 companies · $308 in 2025
The $308 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.31 · 2020: $8.82 · 2021: $127 · 2022: $367 · 2023: $208 · 2024: $344 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $861.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $860.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $695.36 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $260.53 | 2022-2024 | Xarelto |
| Kiniksa Pharmaceuticals International, Plc | $107.38 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $104.56 | 2025 | Camzyos, Eliquis |
| Teva Pharmaceuticals USA, INC. | $42.54 | 2025 | Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $40.59 | 2024-2025 | Brilinta |
| Alexion Pharmaceuticals, INC. | $32.59 | 2021 | |
| Edwards Lifesciences Corporation | $32.40 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $29.49 | 2023 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $28.14 | 2022 | |
| Lilly USA, LLC | $27.87 | 2024 | Zepbound, Mounjaro |
| Esperion Therapeutics, INC. | $21.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adel Metry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.